Wednesday, April 09, 2008

Amag Pharma (NASDAQ:AMAG): Downgraded to Sell at Merrill Lynch

Merrill saying it's worth $21 to $29. They now see potential for a delayed launch til 2011.

This thing could be down 10%+ today.


PS: One NCN member has some interesting comments on the AMAG downgrade.

It's the third time hes downgraded it in 10 weeks - first Jan 30 then Feb 28 and now. Nothing new in the report. Also the analyst was hired by Merrill only last year and I think the guy's trying to make a name for himself.

Jan 30 he went from a $100 target to $78 the stock fell 6 points. Than Feb 28 he went to Neutral and stock fell $4 I think.

I'm just saying the whole street knows he has it out for AMAG.

Notablecalls: Excellent colour.

No comments: